US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...